Dornase alpha and exhaled NO in cystic fibrosis

Hartmut Grasemann, Hildegard Lax, Jennifer W. Treseler, Andrew Colin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Nitric oxide (NO) that is produced within the airways can be measured in the exhaled air. Concentrations of exhaled NO (FENO) are decreased in cystic fibrosis (CF) and, in cross sectional studies, have been shown to be even lower in patients with more advanced pulmonary disease. This may result from retention and metabolisation of NO within viscous airway secretions. Treatment with recombinant human DNase I (dornase alpha) modifies the rheological properties of airway secretions and thereby improves pulmonary function even in young and apparently healthy patients with CF. We studied FENO and pulmonary function in children with CF with little clinical evidence of lung morbidity in a two-year randomized double-blind placebo-controlled study with nebulized dornase alpha. Mean age at enrollment was 8 years (range 6 to 11 years), mean forced vital capacity (FVC) was 112% (range 86 to 133%), and mean forced expiratory volume in one second (FEV 1) was 109% (range 88 to 128%) of predicted values. In five of six (83%) of the dornase alpha treated patients, FENO changed in parallel to changes in pulmonary function tests while no such correlation was observed in any of the eight patients receiving placebo. This difference between treatment groups was statistically significant for both FVC (P = 0.026, Wilcoxon-test) and FEV1 (P = 0.042). These data suggest that FE NO may serve as a surrogate measure for evaluating the effectiveness of interventions that affect airway clearance in CF.

Original languageEnglish
Pages (from-to)379-385
Number of pages7
JournalPediatric Pulmonology
Volume38
Issue number5
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

Cystic Fibrosis
Nitric Oxide
Vital Capacity
Lung
Placebos
Deoxyribonuclease I
Respiratory Function Tests
Forced Expiratory Volume
Lung Diseases
Cross-Sectional Studies
Air
Morbidity
dornase alfa
Therapeutics

Keywords

  • Children
  • Cystic fibrosis
  • Dornase alpha
  • Long term follow-up
  • Nitric oxide
  • NO
  • Pulmozyme

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Grasemann, H., Lax, H., Treseler, J. W., & Colin, A. (2004). Dornase alpha and exhaled NO in cystic fibrosis. Pediatric Pulmonology, 38(5), 379-385. https://doi.org/10.1002/ppul.20088

Dornase alpha and exhaled NO in cystic fibrosis. / Grasemann, Hartmut; Lax, Hildegard; Treseler, Jennifer W.; Colin, Andrew.

In: Pediatric Pulmonology, Vol. 38, No. 5, 01.11.2004, p. 379-385.

Research output: Contribution to journalArticle

Grasemann, H, Lax, H, Treseler, JW & Colin, A 2004, 'Dornase alpha and exhaled NO in cystic fibrosis', Pediatric Pulmonology, vol. 38, no. 5, pp. 379-385. https://doi.org/10.1002/ppul.20088
Grasemann H, Lax H, Treseler JW, Colin A. Dornase alpha and exhaled NO in cystic fibrosis. Pediatric Pulmonology. 2004 Nov 1;38(5):379-385. https://doi.org/10.1002/ppul.20088
Grasemann, Hartmut ; Lax, Hildegard ; Treseler, Jennifer W. ; Colin, Andrew. / Dornase alpha and exhaled NO in cystic fibrosis. In: Pediatric Pulmonology. 2004 ; Vol. 38, No. 5. pp. 379-385.
@article{3e03961878394d26970fd19288d4787d,
title = "Dornase alpha and exhaled NO in cystic fibrosis",
abstract = "Nitric oxide (NO) that is produced within the airways can be measured in the exhaled air. Concentrations of exhaled NO (FENO) are decreased in cystic fibrosis (CF) and, in cross sectional studies, have been shown to be even lower in patients with more advanced pulmonary disease. This may result from retention and metabolisation of NO within viscous airway secretions. Treatment with recombinant human DNase I (dornase alpha) modifies the rheological properties of airway secretions and thereby improves pulmonary function even in young and apparently healthy patients with CF. We studied FENO and pulmonary function in children with CF with little clinical evidence of lung morbidity in a two-year randomized double-blind placebo-controlled study with nebulized dornase alpha. Mean age at enrollment was 8 years (range 6 to 11 years), mean forced vital capacity (FVC) was 112{\%} (range 86 to 133{\%}), and mean forced expiratory volume in one second (FEV 1) was 109{\%} (range 88 to 128{\%}) of predicted values. In five of six (83{\%}) of the dornase alpha treated patients, FENO changed in parallel to changes in pulmonary function tests while no such correlation was observed in any of the eight patients receiving placebo. This difference between treatment groups was statistically significant for both FVC (P = 0.026, Wilcoxon-test) and FEV1 (P = 0.042). These data suggest that FE NO may serve as a surrogate measure for evaluating the effectiveness of interventions that affect airway clearance in CF.",
keywords = "Children, Cystic fibrosis, Dornase alpha, Long term follow-up, Nitric oxide, NO, Pulmozyme",
author = "Hartmut Grasemann and Hildegard Lax and Treseler, {Jennifer W.} and Andrew Colin",
year = "2004",
month = "11",
day = "1",
doi = "10.1002/ppul.20088",
language = "English",
volume = "38",
pages = "379--385",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Dornase alpha and exhaled NO in cystic fibrosis

AU - Grasemann, Hartmut

AU - Lax, Hildegard

AU - Treseler, Jennifer W.

AU - Colin, Andrew

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Nitric oxide (NO) that is produced within the airways can be measured in the exhaled air. Concentrations of exhaled NO (FENO) are decreased in cystic fibrosis (CF) and, in cross sectional studies, have been shown to be even lower in patients with more advanced pulmonary disease. This may result from retention and metabolisation of NO within viscous airway secretions. Treatment with recombinant human DNase I (dornase alpha) modifies the rheological properties of airway secretions and thereby improves pulmonary function even in young and apparently healthy patients with CF. We studied FENO and pulmonary function in children with CF with little clinical evidence of lung morbidity in a two-year randomized double-blind placebo-controlled study with nebulized dornase alpha. Mean age at enrollment was 8 years (range 6 to 11 years), mean forced vital capacity (FVC) was 112% (range 86 to 133%), and mean forced expiratory volume in one second (FEV 1) was 109% (range 88 to 128%) of predicted values. In five of six (83%) of the dornase alpha treated patients, FENO changed in parallel to changes in pulmonary function tests while no such correlation was observed in any of the eight patients receiving placebo. This difference between treatment groups was statistically significant for both FVC (P = 0.026, Wilcoxon-test) and FEV1 (P = 0.042). These data suggest that FE NO may serve as a surrogate measure for evaluating the effectiveness of interventions that affect airway clearance in CF.

AB - Nitric oxide (NO) that is produced within the airways can be measured in the exhaled air. Concentrations of exhaled NO (FENO) are decreased in cystic fibrosis (CF) and, in cross sectional studies, have been shown to be even lower in patients with more advanced pulmonary disease. This may result from retention and metabolisation of NO within viscous airway secretions. Treatment with recombinant human DNase I (dornase alpha) modifies the rheological properties of airway secretions and thereby improves pulmonary function even in young and apparently healthy patients with CF. We studied FENO and pulmonary function in children with CF with little clinical evidence of lung morbidity in a two-year randomized double-blind placebo-controlled study with nebulized dornase alpha. Mean age at enrollment was 8 years (range 6 to 11 years), mean forced vital capacity (FVC) was 112% (range 86 to 133%), and mean forced expiratory volume in one second (FEV 1) was 109% (range 88 to 128%) of predicted values. In five of six (83%) of the dornase alpha treated patients, FENO changed in parallel to changes in pulmonary function tests while no such correlation was observed in any of the eight patients receiving placebo. This difference between treatment groups was statistically significant for both FVC (P = 0.026, Wilcoxon-test) and FEV1 (P = 0.042). These data suggest that FE NO may serve as a surrogate measure for evaluating the effectiveness of interventions that affect airway clearance in CF.

KW - Children

KW - Cystic fibrosis

KW - Dornase alpha

KW - Long term follow-up

KW - Nitric oxide

KW - NO

KW - Pulmozyme

UR - http://www.scopus.com/inward/record.url?scp=7044235828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044235828&partnerID=8YFLogxK

U2 - 10.1002/ppul.20088

DO - 10.1002/ppul.20088

M3 - Article

C2 - 15390350

AN - SCOPUS:7044235828

VL - 38

SP - 379

EP - 385

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 5

ER -